Lite Strategy, Inc. (LITS) - Total Assets
Based on the latest financial reports, Lite Strategy, Inc. (LITS) holds total assets worth $113.34 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Lite Strategy, Inc. net assets for net asset value and shareholders' equity analysis.
Lite Strategy, Inc. - Total Assets Trend (2021–2025)
This chart illustrates how Lite Strategy, Inc.'s total assets have evolved over time, based on quarterly financial data.
Lite Strategy, Inc. - Asset Composition Analysis
Current Asset Composition (June 2025)
Lite Strategy, Inc.'s total assets of $113.34 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Lite Strategy, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Lite Strategy, Inc..
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lite Strategy, Inc.'s current assets represent 100.0% of total assets in 2025, an increase from 94.7% in 2021.
- Cash Position: Cash and equivalents constituted 98.5% of total assets in 2025, up from 4.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Lite Strategy, Inc. Competitors by Total Assets
Key competitors of Lite Strategy, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Lite Strategy, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.39 | 9.66 | 8.23 |
| Quick Ratio | 12.39 | 9.66 | 8.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $12.17 Million | $24.87 Million | $58.13 Million |
Lite Strategy, Inc. - Advanced Valuation Insights
This section examines the relationship between Lite Strategy, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.37 |
| Latest Market Cap to Assets Ratio | 2.25 |
| Asset Growth Rate (YoY) | -55.8% |
| Total Assets | $18.29 Million |
| Market Capitalization | $41.20 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Lite Strategy, Inc.'s assets at a significant premium (2.25x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Lite Strategy, Inc.'s assets decreased by 55.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lite Strategy, Inc. (2021–2025)
The table below shows the annual total assets of Lite Strategy, Inc. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $18.29 Million | -55.81% |
| 2024-06-30 | $41.38 Million | -65.75% |
| 2023-06-30 | $120.81 Million | -32.07% |
| 2022-06-30 | $177.84 Million | +2.15% |
| 2021-06-30 | $174.10 Million | -- |
About Lite Strategy, Inc.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.